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A core outcome set for studies evaluating
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Abstract
Background: Trials of interventions to prevent or treat delirium in adults in an acute hospital setting report
heterogeneous outcomes. Our objective was to develop international consensus among key stakeholders for a core
outcome set (COS) for future trials of interventions to prevent and/or treat delirium in adults with an acute care
hospital admission and not admitted to an intensive care unit.
Methods: A rigorous COS development process was used including a systematic review, qualitative interviews,
modified Delphi consensus process, and in-person consensus using nominal group technique (registration http://
www.comet- initiative.org/studies/details/796).
Participants in qualitative interviews were delirium survivors or family members. Participants in consensus methods
comprised international representatives from three stakeholder groups: researchers, clinicians, and delirium survivors
and family members.
Results: Item generation identified 8 delirium-specific outcomes and 71 other outcomes from 183 studies, and 30
outcomes from 18 qualitative interviews, including 2 that were not extracted from the systematic review. De-
duplication of outcomes and formal consensus processes involving 110 experts including researchers (N = 32),
clinicians (N = 63), and delirium survivors and family members (N = 15) resulted in a COS comprising 6 outcomes:
delirium occurrence and reoccurrence, delirium severity, delirium duration, cognition, emotional distress, and
health-related quality of life. Study limitations included exclusion of non-English studies and stakeholders and small
representation of delirium survivors/family at the in-person consensus meeting.
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Conclusions: This COS, endorsed by the American and Australian Delirium Societies and European Delirium
Association, is recommended for future clinical trials evaluating delirium prevention or treatment interventions in
adults presenting to an acute care hospital and not admitted to an intensive care unit.
Keywords: Delirium, Hospitalization, Core outcome set, Clinical trials
Background
Adults requiring admission to an acute care hospital
who are at risk of delirium comprise a heterogeneous
group including those undergoing major surgery [1],
older adults with non-surgical indications for acute hos-
pital admission such as pneumonia and urosepsis [2],
and in recent times the SARS-CoV-2 virus [3]. Delirium
is a syndrome characterized by fluctuating mental status
with marked inattention and other cognitive disturbance
[4] that is attributable to one or more etiologies. Post-
operative delirium is a common complication, with
prevalence as high as 50% depending on surgery type
and patient risk [2]. Among older adults admitted to an
acute care hospital ward, 1 in 5 experience delirium [5].
The consequences of delirium are serious and include
neurocognitive disturbance and cognitive decline [6],
prolonged hospitalization [7], discharge to post-acute
care facilities, increased caregiver burden [8], decreased
functional status [9, 10], adverse events such as falls
[11], and mortality [12, 13]. As delirium persists, the risk
of mortality at 6 months increases [14]. Many patients
whose hospitalization is complicated by delirium never
return to baseline functional status. Delirium poses sub-
stantial additional costs to healthcare systems; with US
healthcare costs attributable to delirium estimated to ex-
ceed $182 billion annually [15, 16].
While strong evidence indicates delirium is partially
preventable through multi-component nonpharmacolo-
gic approaches [17], pharmacological prevention or
treatment strategies have yet to be proven effective [18,
19]. Disparate outcome selection in trials evaluating the
same intervention is an important barrier to effectively
synthesizing study results, precluding the ability to de-
veloping evidence-based practices and policies [20, 21].
Core outcomes sets (COS) are an agreed-upon mini-
mum set of outcomes to be measured and reported in
all studies relating to a specific health condition [22].
COS offer a solution to reducing heterogeneity of trial
outcome selection. Therefore, our objective was to
undertake a rigorous international consensus process for
a COS for trials of interventions, designed to prevent
and/or treat delirium, for adults requiring an acute care
hospital admission, but who do not require intensive
care unit (ICU) admission. We elected to develop a sin-
gle COS for prevention and treatment trials as many
evaluate an intervention as a continuum of prevention
to treatment, particularly in participant groups (those
receiving anesthesia or sedation, or those with concomi-
tant cognitive issues) in whom early confirmation of de-
lirium is challenging. We excluded trials conducted in
the ICU in this COS as we hypothesized outcomes spe-
cific to critically ill patients such as ventilation duration
might be considered important.
Methods
We followed Core Outcome Measures in Effectiveness
Trials (COMET) guidelines [23] for this COS develop-
ment study and report on it in accordance with Core
Outcome Set–STAndards for Reporting [24]. To com-
mence the item generation process required for a COS,
we conducted a systematic review of outcomes reported
in published trials (1980 to December 2016) and regis-
tered trial protocols (January 2014 to December 2016)
via (1) search term development in collaboration with
two senior information specialists and conduct of the
search across ten publication databases and grey
literature; (2) two authors independently screening
citations and extracting data on study characteristics,
outcomes, and measures (with a third author as arbiter
if needed); and (3) assignment of outcomes according to
COMET taxonomy [25]. We included randomized,
quasi-randomized, or non-randomized intervention
studies of pharmacological (e.g., haloperidol) or non-
pharmacological (e.g., reorientation, music) interventions
for delirium prevention, treatment, or both, conducted
in adults or children experiencing an acute hospital ad-
mission. We excluded studies conducted in ICUs and
those reporting interventions to treat pediatric or adult
agitation on emergence from general anesthesia. In
addition, our item generation process included semi-
structured qualitative interviews exploring outcomes
important to delirium survivors and family members.
Item reduction and consensus methods comprised a
two-round, web-based modified Delphi consensus
process. To gain final consensus, this Delphi process was
followed by an in-person consensus meeting, hosted by
the European Delirium Association, using a modified
nominal group technique [26].
Recruitment of participants for qualitative interviews,
Delphi panel, and consensus meeting
We sought a purposive and international sample from
three stakeholder groups: (1) clinical researchers, (2)
clinicians, and (3) delirium survivors and family. We
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recruited delirium survivor and family participants using
a multi-modal strategy, including a designated study
Twitter account, snowballing (i.e., research participants
passing on recruitment materials to other potential par-
ticipants), and personal contacts. Our multi-modal strat-
egy to recruit expert clinicians and delirium researchers
included recruitment flyers sent through membership
lists of the American Delirium Society and Australian
Delirium Association and to attendees of the European
Delirium Association 2019 meeting (in-person consen-
sus meeting), announcements at the American Delirium
Society 2019 meeting, personalized recruitment emails
sent to corresponding authors of studies included in our
systematic review, flyers posted in UK National Health
Service organizations, snowballing, and personal
contacts.
Semi-structured interviews
Semi-structured interviews with delirium survivors and
family members were conducted by telephone by a sin-
gle experienced interviewer (LR). The interview guide in-
corporated COMET plain language [27] to orient
participants to the terms “study outcomes” and “COS.”
Interviews were audio recorded, transcribed verbatim,
and content analyzed by one author [28].
Delphi methods
Item reduction for identified outcomes occurred via de-
duplication (i.e., removing redundant outcomes), remov-
ing outcomes related to aggregate population data rather
than individual patient outcomes (e.g., number of pa-
tients receiving analgesia), and grouping similar out-
comes [29]. We grouped into a single outcome those
describing adverse events, side effects, and complica-
tions, and those describing study-related feasibility or
process outcomes. As more items are associated with
lower COS Delphi response rates [30], we further re-
duced outcomes by removing those identified in < 5% of
studies, unless specifically mentioned in survivor/family
member interview transcripts. The final list of outcomes
was then reviewed for wording clarity (with lay descrip-
tions of medical terms to aid understanding) and for do-
main grouping.
To conduct the Delphi, we used the bespoke Delphi-
Manager software, Version 4 (COMET Initiative, Liver-
pool, UK). Participants were directed to self-select their
Fig. 1 PRISMA flow diagram
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key stakeholder group (i.e., patient/family; clinician; re-
searcher) and to score the importance of each outcome
for COS inclusion, without consideration of measurabil-
ity or feasibility. Importance was scored using the Grad-
ing of Recommendations Assessment, Development and
Evaluations (GRADE) Scale [31]. This is a 9-point Likert
scale with scores 1 to 3 considered not important, 4 to 6
important but not critical, and 7 to 9 as critical for inclu-
sion. This scoring method is recommended by COMET
to facilitate maximum discrimination between question-
naire items [32, 33]. Participants were provided an
“Unable to Score” response option and the opportunity
to suggest additional outcomes. To avoid presentation
bias, the DelphiManager software randomized outcome
domain presentation order.
For Delphi round 1 scores, we calculated mean and
standard deviation (SD) of GRADE importance scores
and determined the proportion of participants rating
each outcome with scores of 7 to 9 (critically important),
4 to 6 (important but not critical), and 1 to 3 (not im-
portant) for the entire expert panel, and separately for
each stakeholder group. Additional suggested outcomes
were deduplicated and worded appropriately for inclu-
sion in round 2. For round 2, participants received their
own round 1 scores and summarized scores, with visual
representation using histograms. Participants were asked
to re-score outcome importance. If a participant chan-
ged their scoring so that it moved into a new category
(e.g., from “important but not critical” to “critical for in-
clusion”), participants were requested to provide a free-
text reason for this change. For both rounds, we sent
three email reminders regarding completion using the
DelphiManager software.
In-person consensus meeting and nominal group
technique
To inform our in-person consensus meeting, we calcu-
lated mean (SD) Delphi round 2 importance scores and
determined the proportion of participants rating each
outcome as critical for inclusion overall and by stake-
holder group. As recommended by COMET [22],
outcomes brought to the consensus meeting met the
following criteria: scored as “critical for inclusion” by ≥
70% of respondents and “not important” by < 15% con-
sidering all participants and for each of the three key
stakeholder groups. No outcome that was rated by <
70% of participants as critically important overall or
within a stakeholder group was brought forward to the
consensus meeting.
For pragmatic reasons, we timed our consensus meet-
ing with the 2019 European Delirium Association annual
conference. We provided an overview of our meeting’s
aim and structure and the Delphi results. We provided
the importance scoring for the outcomes by stakeholder
group to consensus meeting participants, for consider-
ation during outcome ranking. Using nominal group
technique methods, we held iterative rounds of small
group and then whole group discussion. To avoid negat-
ing the Delphi process, participants were not permitted
to suggest new outcomes. Participants ranked outcomes
from most critical to least critical for COS inclusion at
the end of each discussion.
The study was funded by the Canadian Institutes of
Health Research. It received approval from the Research
Ethics Boards of the University of Toronto, King’s
Table 1 Systematic review study characteristics
N = 183 studies n (%)
Study design
RCT 128 (70)
Before and after intervention study 29 (16)
Non-randomized controlled trial 19 (10)
Othera 7 (4)
Study region





South America 2 (1)
Multiple 1 (1)
Study population
Adults only 183 (100)









Prevention only 125 (68)
Treatment only 18 (10)
Both 44 (22)
Study intervention
Pharmacological agent to prevent and/or treat delirium 87 (48)
Protocol or bundle to prevent and/or treat delirium 80 (44)
Non-pharmacological to prevent and/or treat delirium 16 (9)
aOther comprised: 5 interventional cohort studies with controls, 1 quasi RCT,
and 1 interrupted time series study
Percentages may not sum to 100 due to rounding
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College London, Sunnybrook Health Sciences Centre
(Toronto, Canada), and the UK Health Research Author-
ity (HRA) and Health and Care Research Wales
(HCRW). Ethics approvals to recruit via social media,
snowballing, and networking methods enabled recruit-
ment from multiple countries including the USA,
Europe, Asia, Oceania, and South America. Written in-
formed consent was obtained from all study participants.
The Del-CORs project is registered with the COMET
initiative (http://www.comet- initiative. org/studies/de-
tails/796). We previously published the study protocol
[34].
Results
Item generation via systematic review
We screened 18,933 citations, identified and extracted
data pertaining to study outcomes and measures from
183 studies meeting our inclusion criteria (Fig. 1). Of the
183 included studies, 150 (88%) recruited older adults
only (classified according to the study author’s partici-
pant description); most (109/183, 60%) were in post-
operative patients. Delirium prevention was the primary
intervention aim for 125 (68%) studies (Table 1). We ex-
tracted information on 79 outcomes reported in more
than one study. These included 8 delirium-specific
Table 2 Outcomes identified by delirium survivor and family interview participants
Outcome (N = 18 interview participants) n (%)
Emotional distress (i.e., fear and anxiety related to delirium symptoms) 9 (50)
Delirium severity (i.e., severity of hallucinations, paranoid thoughts, delusions, disorientation) 9 (50)
Ability to get back to previous cognitive abilities/long term cognitive outcomes 8 (44)
Agitation—occurrence and durationa 8 (44)
Safety—falls and other injuries, pulling out lines 8 (44)
Ability to live alone independently/manage activities of daily living 7 (39)
Being able to mobilize/physical functioning after discharge 7 (39)
Risk factors for delirium including environmental factorsb 6 (33)
Delirium duration 5 (28)
Repeated infection as a risk factor for deliriumb 5 (28)
Delirium reoccurrence and its risk factorsb 5 (28)
Sleep quantity and quality 5 (28)
Quality of life/recovery (physical and psychological) 5 (28)
Acute stress and post-traumatic stress disorder 4 (22)
Impact of delirium on family (stress, emotional wellbeing, burden)a 4 (22)
Length of stay 3 (17)
Mortality/survival 3 (17)
Use of chemical restraint/psychotropic drugs 3 (17)
Pain 3 (17)
Discharge disposition including ability to be discharged home 3 (17)
Time to/frequency of mobilization 3 (17)
Use of physical restraint 2 (11)
Ability to return to previous lifestyle/workc 2 (11)
Time to delirium diagnosis 2 (11)
Depression 1 (6)
Sedative dose 1 (6)
Delirium incidence 1 (6)
Delirium resolution 1 (6)
Subsyndromal deliriumc 1 (6)
Hospital readmission 1 (6)
aIdentified in systematic review but reported in < 5% of studies
bConsidered as not an outcome during adjudication processes
cNot identified in systematic review
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outcomes (Additional File Table 1) and 71 other out-
comes categorized using COMET taxonomy [25] (Add-
itional File Table 2).
Item generation via interviews with delirium survivors
and family members
We recruited 18 delirium survivors or family members
from Canada, USA, and UK. From these interviews, 30
potential outcomes were identified (Table 2). The most
commonly identified outcomes in the interview dataset
were (1) “emotional distress, i.e., fear and anxiety related
to delirium symptoms such as delusions” and (2) “delir-
ium severity” (both identified by 50% of interview partic-
ipants). Only two outcomes, “ability to return to
previous lifestyle/work” and “subsyndromal delirium”
(named as such by a family member with medical back-
ground) were not identified in the systematic review and
brought forward for consideration for inclusion in the
round 1 Delphi.
Consensus building
Deduplication decisions (Additional File Table 3) re-
sulted in selection of 31 outcomes for the Delphi round
1 (see outcomes listed in Additional File Table 4). We
recruited 110 participants for the Delphi international
expert panel; 15 (14%) were delirium survivors or family
members of whom 7 were also healthcare providers or
researchers (Table 3). Of the 31 outcomes provided in
round 1, 20 (65%) met a priori consensus criteria for
COS inclusion considering all participant responses, 8
(26%) by all three stakeholder groups (Additional file 1:
Table 4). Compared to clinicians or survivors/family, re-
searchers were less likely to consider outcomes critical
for inclusion that related to emotional well-being, sleep,
or agitation and its management (i.e., physical restraint).
For Delphi round 2, 8 additional outcomes were in-
cluded based on suggestions in round 1. These included
(1) development of incontinence, (2) nutritional status,
(3) workload, (4) use of sitters, (5) family caregiver bur-
den, (6) staff satisfaction, (7) new onset dementia, and
(8) ability to participate in rehabilitation. Of the 110
round 1 participants, 77 (70%) participated in round 2.
Of the 39 outcomes provided, 22 (56%) met consensus
criteria for inclusion in the COS considering all partici-
pant responses, 17 (44%) by all three stakeholder groups
(Table 4). Of the 8 added outcomes, none met inclusion
criteria.
Twelve experts (including 1 delirium survivor) partici-
pated in the in-person consensus meeting. After the first
round of small and then large group discussion using
nominal group technique ranking exercises, 6 of the 17
(35%) outcomes were excluded. “Falls and other injuries”
and “agitation” were voted out by one small group but
not the second. On further discussion and ranking, these
outcomes as well as mortality (causes of falls and mor-
tality were considered multi-factorial and not delirium
specific) were excluded. Delirium occurrence and re-
occurrence was collapsed into a single outcome. The 6
outcomes selected for the COS for trials of interventions
to prevent and/or treat delirium in adults requiring an
acute care hospital admission comprised: (1) delirium
occurrence and reoccurrence, (2) delirium severity, (3)
delirium duration, (4) cognition, (5) emotional distress,
and (6) health-related quality of life (Fig. 2).
Discussion
This study is the first to establish a COS for use in
future efficacy and effectiveness trials of interventions
focused on preventing and/or treating delirium expe-
rienced by adults required an acute care hospital
admission, without an ICU admission. This study
rigorously followed established COMET methods for
COS development. We used systematic review
methods and qualitative interviews with delirium sur-
vivors and family members to generate a comprehen-
sive list of potential outcomes. Robust consensus
building (Delphi and nominal group technique)
methods were then used to establish six outcomes for
inclusion in the final COS. This COS addresses one
Table 3 Round 1 Delphi participants




Australia and New Zealand 20 (18)
Europe 11 (10)
Canada 11 (10)
South America 3 (3)
Asia/Middle East 3 (3)
Involvement with delirium
Research and clinical work 73 (66)
Clinical work only 17 (15)
Delirium survivors and family members 15 (14)
Research work only 5 (5)
Profession of healthcare profession participants (N = 90)
Physician 66 (73)
Nurse or nurse practitioner 14 (16)
Other healthcare profession 6 (7)
Physio, respiratory, or occupational therapist 4 (4)
Years of clinical experience (N = 90)
> 10 73 (81)
6–10 13 (14)
3–5 4 (4)
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of the priority areas identified by the 2019 Scientific
Think Tank report from NIH-funded Network for In-
vestigation of Delirium: Unifying Scientists (NIDUS)
group [35] and an Agency for Healthcare Research
and Quality report recommendation [36]. The use of
this COS in future trials of hospitalized adults is en-
dorsed by the American and Australian Delirium
Societies and European Delirium Association.
Table 4 Round 2 Delphi scores
Outcomes Overall Survivor/family (N = 7) Clinician (N = 42) Researcher (N = 28)
Mean (SD) % critical % critical % critical % critical
Delirium occurrence 8.6 (0.8) 97 86 98 100
Delirium duration 8.0 (1.0) 95 86 95 96
Adverse events/side effects 8.0 (1.0) 95 86 97 93
Mortality 8.3 (1.0) 93 100 90 96
Cognitive status 8.1 (1.0) 92 100 88 96
Delirium severity 8.0 (1.0) 92 100 93 89
Delirium resolution 7.7 (1.1) 87 71 93 82
Agitation 7.5 (1.2) 87 100 92 75
Use of antipsychotics/other medication for agitation 7.6 (1.3) 84 86 88 79
Activities of daily living 7.7 (1.2) 83 71 88 86
Patient emotional wellbeing 7.5 (1.1) 82 100 85 71
Sleep 7.4 (1.3) 81 100 85 70
Hospital disposition 7.6 (1.3) 80 71 80 71
Falls and other injuries 7.6 (1.4) 80 100 80 75
Physical restraint 7.4 (1.6) 79 86 88 64
Physical functioning 7.3 (1.2) 78 71 78 79
Delirium reoccurrence 7.4 (1.3) 78 86 83 68
Length of stay 7.4 (1.3) 78 86 81 71
Hospital readmission 7.3 (1.4) 75 71 76 75
Health-related quality of life 7.2 (1.2) 75 100 83 57
Sedation score/level indicating quality of sedation 7.1 (1.5) 73 86 74 67
New onset dementia 7.0 (1.6) 71 100 64 71
Costs 7.0 (1.4) 64 57 67 61
Caregiver burden 6.8 (1.4) 61 71 66 50
Pain score/level indicating quality of analgesia 6.8 (1.5) 58 86 60 48
Pressure ulcers 6.7 (1.3) 52 71 53 46
Delirium type 6.5 (1.5) 50 86 44 50
Analgesic drug use 6.6 (1.5) 49 71 50 41
Ability to participate in rehab 6.5 (1.7) 48 71 46 46
Pneumonia 6.7 (1.4) 45 71 43 43
Time to delirium onset 6.3 (1.6) 45 86 54 21
Patient/family satisfaction 6.3 (1.5) 40 86 49 14
Workload 6.1 (1.6) 40 83 41 25
Study intervention related process outcomes 6.2 (1.4) 39 29 37 36
Use of sitters 6.0 (1.6) 39 71 36 30
Family emotional wellbeing 6.2 (1.3) 36 71 49 7
Nutritional status 6.0 (1.6) 36 71 32 32
Staff satisfaction 5.7 (1.7) 32 71 26 25
Incontinence 5.8 (1.4) 31 43 33 25
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This COS includes three outcomes that characterize
delirium itself, i.e., “occurrence and reoccurrence,” “se-
verity,” and “duration.” Measurement of delirium occur-
rence, an umbrella term for incidence and prevalence, is
imperative to determine the effect of interventions de-
signed to prevent delirium. Delirium reoccurrence is
relevant to trials of interventions designed to treat delir-
ium. Fear of delirium reoccurrence was emphasized in
interviews with delirium survivors and family members
further highlighting the emotional distress associated
with delirium. Inclusion of delirium severity reflects
growing interest in its measurement as a way of under-
standing symptom burden, risk stratification, selection of
appropriate interventions, clinical course, and prognosis
[37]. Greater delirium severity is associated with worse
outcomes, such as discharge to a post-acute healthcare
facility and death. Similarly prolonged delirium duration
is associated with worse outcomes after hospital dis-
charge [38].
Inclusion of “cognition” and “health-related quality of
life” as core outcomes is understandable considering that
delirium is associated with long-term cognitive decline,
including incident dementia in older adults, and has an
adverse impact on health-related quality of life [6]. Simi-
larly, inclusion of “emotional distress” is reasonable as
delirium can cause considerable subjective distress such
as fear, anxiety, depression, and post-traumatic stress
disorder [39]. Emotional distress at the time of delirium
may manifest as psychomotor agitation, an outcome that
was ranked highly in the Delphi rounds despite being
voted out of the final COS. Emotional distress and bur-
den to family members is also substantial [40]; however,
researcher participants in our study, in particular, rated
this outcome as unimportant for COS inclusion. How-
ever, the COS represents the minimum set of outcomes
recommended for inclusion in all studies; hence, these
outcomes can be included in future studies despite not
included in the final COS.
A group with high delirium prevalence is the critically
ill [41]. Our group recently completed a COS for future
trials of interventions for preventing or treating delirium
experienced by critically ill adults [42]. Interestingly, the
Fig. 2 Development of COS for trials of interventions to prevent or treat delirium in hospitalized adults
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outcomes selected for this COS, that used the same pro-
cesses but an expert panel with experience of critical
care, were similar, with five outcomes included in both
COS. Rather than “delirium duration,” participants in
the critical care COS selected the outcome “time to de-
lirium resolution” as this was felt more indicative of the
end of delirium. Mortality was included as a seventh
outcome which likely reflects the increased risk of death
of critically ill patients [43]. Ongoing work for both
these COS is to establish the measurement instruments
and the time horizon for measurement for each of the
outcomes.
Strengths of this study are inclusion of interviews
with delirium survivors and family members in the
item generation phase, a relatively large and inter-
national stakeholder panel, and adherence to COMET
COS development methods. Study limitations include
exclusion of non-English studies reporting outcomes
as well as observational studies and non-English
speaking research participants. International represen-
tation in the interview phase was limited to three na-
tions. The majority of published studies included in
our systematic review phase included post-operative
patients which may limit the generalizability of our
findings. Our decision to exclude outcomes identified
in < 5% of studies with our systematic review may
have led to exclusion of important outcomes. How-
ever, this was mitigated by their inclusion if men-
tioned in survivor/family member interviews and
enabling Delphi round 1 participants to suggest add-
itional outcomes for consideration. We did not ask
Delphi participants to identify themselves as a sur-
vivor or family member. As such, we cannot confirm
if we have sufficient representation of these distinct
groups. Due to the timing of the Delphi and the in-
person consensus meeting, we were unable to conduct
a third Delphi round confirming importance scores of
the eight additional outcomes suggested in round 1.
Although patient and family representation in the
Delphi was reasonable, only one delirium survivor
was able to attend the in-person consensus meeting.
Conclusion
With development of this COS, we seek to promote
standardized outcome selection and reporting in future
trials of interventions to prevent and/or treat delirium in
adults experiencing an acute care hospital admission and
without an ICU admission. We anticipate widespread
dissemination and adoption of this COS will facilitate
faster detection of effective interventions to prevent or
treat delirium due to enhanced ability to pool trial data,
ultimately improving patient outcomes. Further work is
now needed to operationally define the six core out-
comes that will include consensus in selecting validated
measurement instruments, the time horizon for meas-
urement, analysis metrics, and method of aggregation.
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